Human CHO-K1/C5a/Gα15 Stable Cell Line

[CAT#: NCL20120050CR]

Complement Component 5A Receptor 1 Stable Cell Line

Species:: Human

Applications:: GPCR Screening

Cell Types:: Other Cells

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Request Pricing

Inquiry

Product Overview

Description

The complement component 5a receptor 1 (C5a) is Gq/11 and Gi/o-coupled GPCRs. C5a is a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy. C5a receptor plays an important role in mediating acute kidney allograft rejection.

Cell Types

Other Cells

Applications

GPCR Screening

Research Areas

GPCR

Species

Human

Properties

Size

>1x10^6 Cells

Form

Frozen cells

Culture Medium

Ham's F12, 10% FBS, 100 μg/ml Hygromycin B, 400 μg/ml G418

Freeze Medium

45% culture medium, 45% FBS, 10% DMSO

Receptor

C5a/C5AR1

Family

Complement peptide receptor

Strain

C5a/Gα15 Cell Line

Cell Purity

>95%

Shipping

Dry ice

Storage

Liquid nitrogen immediately upon delivery

Handling Advice

Avoid inhalation. Avoid contact with eyes, skin, and clothing. Avoid prolonged or
repeated exposure.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Warnings

Store under recommended storage conditions (liquid nitrogen). Do not expose to high temperature. After expiration, discard all remaining reagents.

Target Details

Target

C5a

Official Name

C5a

Alternative Names

C5a1 receptor; C5aR1; CD88; C5R1; C5A; C5AR; complement component 5 receptor 1 (C5a ligand); C5a anaphylatoxin chemotactic receptor; C5a-R; complement C5a receptor; complement component 5; receptor 1; complement component 5a receptor 1; D7Msu1

Gene ID

727(Human)

Uniprot ID

P01031(Human)

References

1. Cui, J., Wang, H., Medina, R., Zhang, Q., Xu, C., Indig, I. H.,.. & Guo, L. (2020). Inhibition of PP2A with LB-100 enhances efficacy of CAR-T cell therapy against glioblastoma. Cancers, 12(1), 139.

Publications